Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer

被引：0
|
作者：
Hirata, Michinari
Tanaka, Yukari
Shinonome, Satomi
Yamada, Tomomi
Torii, Mikinori
Nezasa, Kenichi
Tanaka, Hidekazu
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4073
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Brain metastases in HER2 positive breast cancer: the next hurdle
    Ow, Samuel
    Lee, Soo-Chin
    ANNALS OF PALLIATIVE MEDICINE, 2012, 1 (03) : 198 - 201
  • [32] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Pin Zhang
    Lin Wang
    Yueying Zhen
    Zhihong Wang
    Hesheng Zhang
    Richard Jones
    Binghe Xu
    ChineseJournalofCancerResearch, 2024, 36 (01) : 46 - 54
  • [33] Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer
    Krähn, G
    Leiter, U
    Kaskel, P
    Udart, M
    Utikal, J
    Bezold, G
    Peter, RU
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (02) : 251 - 259
  • [34] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [35] Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
    Hong, Joohyun
    Park, Yeon Hee
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [36] 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
    Hiroaki Kurihara
    Akinobu Hamada
    Masayuki Yoshida
    Schuichi Shimma
    Jun Hashimoto
    Kan Yonemori
    Hitomi Tani
    Yasuji Miyakita
    Yousuke Kanayama
    Yasuhiro Wada
    Makoto Kodaira
    Mayu Yunokawa
    Harukaze Yamamoto
    Chikako Shimizu
    Kazuhiro Takahashi
    Yasuyoshi Watanabe
    Yasuhiro Fujiwara
    Kenji Tamura
    EJNMMI Research, 5
  • [37] 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
    Kurihara, Hiroaki
    Hamada, Akinobu
    Yoshida, Masayuki
    Shimma, Schuichi
    Hashimoto, Jun
    Yonemori, Kan
    Tani, Hitomi
    Miyakita, Yasuji
    Kanayama, Yousuke
    Wada, Yasuhiro
    Kodaira, Makoto
    Yunokawa, Mayu
    Yamamoto, Harukaze
    Shimizu, Chikako
    Takahashi, Kazuhiro
    Watanabe, Yasuyoshi
    Fujiwara, Yasuhiro
    Tamura, Kenji
    EJNMMI RESEARCH, 2015, 5
  • [38] Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
    Zimmer, Alexandra S.
    Steinberg, Seth M.
    Smart, Dee Dee
    Gilbert, Mark R.
    Armstrong, Terri S.
    Burton, Eric
    Houston, Nicole
    Biassou, Nadia
    Gril, Brunilde
    Brastianos, Priscilla K.
    Carter, Scott
    Lyden, David
    Lipkowitz, Stanley
    Steeg, Patricia S.
    FUTURE ONCOLOGY, 2020, 16 (14) : 899 - 909
  • [39] LAPATINIB AND CAPECITABINE IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES
    Dubianski, R.
    Brewczynska, E.
    Lemanska, I.
    Szombara, E.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] Characteristics of patients with brain metastases from HER2-positive breast cancer
    Laakmann, E.
    Witzel, I.
    Neunhoeffer, T.
    Park-Simon, T-W.
    Weide, R.
    Riecke, K.
    Polasik, A.
    Schmidt, M.
    Puppe, J.
    Mundhenke, C.
    Luebbe, K.
    Hesse, T.
    Thill, M.
    Zahm, D-M.
    Denkert, C.
    Fehm, T.
    Nekljudova, V.
    Rey, J.
    Loibl, S.
    Mueller, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S63 - S64
12345